

Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group

Thomas Cash¹ | Elizabeth McIlvaine² | Mark D. Krailo² | Stephen L. Lessnick³ | Elizabeth R. Lawlor⁴ | Nadia Laack⁵ | Joel Sorger⁶ | Neyssa Marina⁷ | Holcombe E. Grier⁸ | Linda Granowetter⁹ | Richard B. Womer¹⁰ | Steven G. DuBois¹¹

¹Department of Pediatrics, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia

²Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California

³Center for Childhood Cancer and Blood Disorders at Nationwide Children's Hospital, and the Division of Hematology, Oncology and BMT at The Ohio State University, Columbus, Ohio

⁴Department of Pediatrics, University of Michigan, Ann Arbor, Michigan

⁵Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota

⁶Department of Orthopedics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

⁷Department of Pediatrics, Stanford University School of Medicine and Lucille Packard Children's Hospital at Stanford, Palo Alto, California

⁸Department of Pediatrics, Children's Hospital Boston/Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts

⁹Department of Pediatrics, NYU School of Medicine and NYU Langone Medical Center, New York

¹⁰Department of Pediatrics, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

¹¹Department of Pediatrics, UCSF School of Medicine and UCSF Benioff Children's Hospital, San Francisco, California

Correspondence

Thomas Cash, Department of Pediatrics, Children's Healthcare of Atlanta, Health Sciences Research Building, Emory University, Brumley Bridge, 3rd Floor, W-350, 1760 Haygood Drive, Atlanta, GA 30322.

Email: Thomas.Cash@choa.org

Grant sponsor: Nick Currey Fund; Grant sponsor: NIH/NCI; Grant number: U10CA98543.

Abstract

Background: The prognostic significance of having extraskeletal (EES) versus skeletal Ewing sarcoma (ES) in the setting of modern chemotherapy protocols is unknown. The purpose of this study was to compare the clinical characteristics, biologic features, and outcomes for patients with EES and skeletal ES.

Methods: Patients had localized ES and were treated on two consecutive protocols using five-drug chemotherapy (INT-0154 and AEWS0031). Patients were analyzed based on having an extraskeletal ($n = 213$) or skeletal ($n = 826$) site of tumor origin. Event-free survival (EFS) was estimated using the Kaplan–Meier method, compared using the log-rank test, and modeled using Cox multivariate regression.

Results: Patients with extraskeletal ES (EES) were more likely to have axial tumors (72% vs. 55%; $P < 0.001$), less likely to have tumors >8 cm (9% vs. 17%; $P < 0.01$), and less likely to be white (81% vs. 87%; $P < 0.001$) compared to patients with skeletal ES. There was no difference in key genomic features (type of *EWSR1* translocation, *TP53* mutation, *CDKN2A* mutation/loss) between groups. After controlling for age, race, and primary site, EES was associated with superior EFS (hazard ratio = 0.69; 95% confidence interval: 0.50–0.95; $P = 0.02$). Among patients with EES, age ≥ 18 , nonwhite race, and elevated baseline erythrocyte sedimentation rate were independently associated with inferior EFS.

Conclusion: Clinical characteristics, but not key tumor genomic features, differ between EES and skeletal ES. Extraskeletal origin is a favorable prognostic factor, independent of age, race, and primary site.

KEYWORDS

extraosseous, extraskeletal Ewing sarcoma, gene expression, gene profiling, prognosis, soft-tissue Ewing sarcoma

1 | INTRODUCTION

Ewing sarcoma (ES) is the second most common malignant bone tumor of childhood, which most commonly arises from bone but can develop in extraskeletal sites. Based on the data from clinical trials and large registry data, extraskeletal ES (EES) accounts for approximately 20–30% of cases.^{1,2} Historically, these patients were treated on rhabdomyosarcoma protocols, however it is now recognized that patients with EES benefit from treatment protocols for patients with ES of the bone.^{2–5}

Previous reports have suggested that there may be clinical differences between patients with EES and skeletal ES.^{1,3,4,6,7} For example, patients with extraskeletal disease have been reported to be older and have a propensity for axial tumor origin. The prognostic significance of having an EES using contemporary treatment protocols remains unclear, though two more recent reports have suggested superior outcomes for these patients.^{1,7} Likewise, it is unknown if the approach to local control of the primary tumor differs based on tissue of origin. Moreover, potential biologic differences between skeletal and extraskeletal tumors remain largely unexplored.

In order to address these gaps in our knowledge, we used a large cohort of patients treated on two consecutive cooperative group clinical trials to compare the clinical features, approach to local control, and outcomes in patients with extraskeletal versus skeletal localized ES. Additionally, we explored potential biologic differences between these two groups, providing a comprehensive evaluation of differences in somatic mutations and gene expression.

2 | METHODS

2.1 | Patients

The cohort included eligible patients treated on all arms of the cooperative group trials INT-0154 and AEWS0031.^{2,8} Eligible patients were those with newly diagnosed, localized ES or primitive neuroectodermal tumor (PNET) of the bone or soft tissue, who were diagnosed based on having histological and/or immunohistochemical findings consistent with ES or PNET. Information regarding translocation status was used as supportive data but was not required for study eligibility. Patients were aged ≤ 30 for INT-0154 and ≤ 50 for AEWS0031. Patients with unknown skeletal versus extraskeletal status were excluded from this analysis. There were no other exclusion criteria. Details of the treatment on these two trials have previously been published, but all patients received alternating cycles of vincristine–doxorubicin–cyclophosphamide and ifosfamide–etoposide given on an every 2- or 3-week basis.

Patients in this analysis were treated primarily at Children's Oncology Group (COG) centers located in the United States and Canada. Institutional Review Board (IRB) approval was obtained locally by each participating center, with written informed consent obtained for all patients prior to enrollment. This secondary analysis utilized deidentified data and was exempted from separate IRB review.

2.2 | Primary predictor variable

Patients were categorized for analysis as having extraskeletal or skeletal ES. For both INT-0154 and AEWS0031, any tumor with any degree of bone involvement was considered a primary bone tumor. Initial designation of extraskeletal origin was based on site report and confirmed by study chair review of baseline imaging reports, when available. For AEWS0031, records of this review were maintained and there were originally 136 patients designated as extraskeletal by the treating facility. Baseline imaging reports were available for the study chair to review in 118 of these 136 patients. For the 18 patients who did not have baseline imaging reports available for review, the original designation of extraskeletal from the treating facility was maintained. Of the 118 patients with available imaging reports, the study chair determined on his review that 17 patients had skeletal tumors, and so these 17 patients were reclassified, resulting in a final cohort of 119 patients with EES from AEWS0031.

2.3 | Outcome variables

Primary sites were categorized into groups based on the involved body compartment. To account for the various extraskeletal locations within a given body compartment, all structures including skin, subcutaneous or connective tissue, lymph nodes, muscles, and organs were included in the given specific site designation. The one exception was sites designated as paraspinal that included primary sites involving or adjacent to the cervical, thoracic, and lumbar spine. The sites were classified as follows: head and neck, thorax and abdomen, pelvis, proximal extremity (proximal humerus through elbow, proximal femur through knee), distal extremity (below elbow through wrist and hand, below knee through ankle and foot), paraspinal, and "other." Primary sites were further categorized for analysis as either axial or nonaxial and pelvic or nonpelvic.

In addition to primary site, the following clinical variables were analyzed: age, sex, race, tumor size, baseline lactate dehydrogenase (LDH), baseline erythrocyte sedimentation rate (ESR), and type of local control. Age was further categorized as either <18 or ≥ 18 ⁹, and tumor size was further categorized as ≤ 8 or >8 cm in maximum dimension. Tumor size data were not collected on AEWS0031. For LDH, the institutional upper limit of normal was used to divide patients into the categories with elevated LDH values and normal values. For ESR, the 75th percentile of the entire cohort was used as a cutpoint to divide patients into the categories at or above the 75th percentile and below. Clinical outcomes of interest included death, second malignancy, relapse/progression, and type of first relapse/progression (local failure, distant failure, or combined failure).

Information regarding tumor biology was also obtained where available and included type of *EWSR1* translocation, as determined in a prior study.¹⁰ Presence or absence of a *TP53* mutation or *CDKN2A* mutation/loss was assessed in a subset of patients included in a retrospective analysis.¹¹ To investigate differences in gene expression between EES and skeletal ES, we interrogated

Affymetrix expression array data from a cohort of 46 patients (GEO: GSE63157).¹²

2.4 | Statistical methods

Categorical variables were compared between patients with EES and skeletal ES using two-sided Fisher exact or chi-squared tests. Continuous variables were compared between groups using the Wilcoxon rank sum test. Patients who had missing data for a given characteristic were not included in the statistical tests for differences between groups.

The primary outcome of interest was event-free survival (EFS) that was defined as the time elapsed between study entry and either the occurrence of an analytic event or the date of the last patient contact, whichever came first. Disease progression, diagnosis of any second malignant neoplasm, and death were considered analytic events. Patients who had not experienced an event as their last contact were considered censored. Overall survival (OS) was a secondary outcome and was defined as time from study entry to death or last follow-up for surviving patients. EFS and OS distributions were estimated by the Kaplan–Meier method. Confidence intervals (CIs) were calculated using the complementary log–log distribution of the Kaplan–Meier estimate. Differences in event risk between groups in the univariate setting were evaluated by the log-rank test. Those baseline variables with a statistically significant effect on EFS based on the log-rank test were considered candidate variables for regression models, though variables with extensive missing data, such as tumor size, were removed from potential consideration. Backwards selection was used to generate a Cox regression model with a threshold *P*-value of 0.05 to be retained in the model. For the regression model containing all patients, the variable defining EES versus skeletal ES was retained throughout all models.

Differences in pattern of relapse between patients with EES and skeletal ES were examined by way of cumulative incidence analysis. The relapse types of interest were local-only progression, distant-only progression, and local plus distant progression. For each relapse type of interest, the cumulative incidence distributions were estimated by the method of Marubini and Valsecchi.¹³ Tests for differences between groups in the incidence of the relapse type of interest were conducted by way of competing risks regression using the method of Fine and Gray.¹⁴

For gene expression studies, differentially expressed genes were identified as described previously.¹² Briefly, nonannotated transcripts and transcripts with low expression in at least 25% of samples (\log_2 signal <2.6) and with low variability across all samples (interquartile range of \log_2 signals <0.5) were excluded. A moderated *t*-test was used to identify differential expression between the remaining 4,615 annotated genes, as described previously.¹² Genes with a fold change of at least 1.5 and a *P*-value of <0.05 were deemed to be differentially expressed. The database for annotation, visualization, and integrated discovery (DAVID) v6.7 was used for the functional enrichment analysis of the differentially expressed.¹⁵ All statistical analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC) and STATA version 12 (StataCorp, College Station, TX).

3 | RESULTS

3.1 | Clinical features differ between EES and skeletal ES

Of the 1,039 localized ES patients included in our analysis, 213 (20.5%) had EES while 826 (79.5%) had skeletal tumors. A comparison of the clinical features by site is shown in Table 1. There was no difference in age at diagnosis between the two groups. Patients with EES were more likely to be nonwhite compared to patients with skeletal ES (14% vs. 6%; $P < 0.001$). The distribution of primary sites differed between the two groups. Patients with EES were more likely to have tumors arising in axial locations (72% vs. 55%; $P < 0.001$), but showed a trend toward having fewer pelvic primary sites (14% vs. 19%; $P = 0.07$). Patients with EES were more likely to have tumors <8 cm (21% vs. 16%; $P < 0.01$). There was no significant difference in baseline LDH and ESR values.

Local control strategies differed between groups. Compared to patients with skeletal ES, those with EES were more likely to receive a combined modality approach (surgery plus radiation) for local control (30% vs. 17%; $P < 0.01$). We evaluated this pattern more closely using data available from AEWS0031. The majority of patients who received a combined modality approach received postoperative radiotherapy, with similar rates between EES and skeletal ES (91% and 83%, respectively). Margin status was available for 65 of the patients from AEWS0031 included in this analysis who received postoperative radiotherapy. Review of these data suggested that a greater proportion of patients with EES treated with postoperative radiotherapy had positive surgical margins compared to skeletal ES (66% vs. 48%).

3.2 | Clinical outcomes differ between EES and skeletal ES

EFS and OS estimates are shown in Figure 1. The 5-year unadjusted EFS for patients with EES was 76% (95% CI: 69–81%) compared to 69% (95% CI: 65–72%) for patients with skeletal ES ($P = 0.05$; Fig. 1A). The 5-year unadjusted OS for patients with EES was 85% (95% CI: 80–90%) compared to 78% (95% CI: 75–81%) for patients with skeletal ES ($P = 0.11$; Fig. 1B). We also performed a sensitivity analysis of EFS focused exclusively on patients treated on AEWS0031 and observed a significantly decreased risk for event for patients with EES compared to skeletal ES (hazard ratio [HR] = 0.52; 95% CI 0.33–0.82; $P = 0.005$).

We constructed a Cox proportional hazards model in the full analytic cohort to assess the prognostic impact of extraskelatal origin while controlling for other known risk factors. After controlling for age, race, and primary site, patients with EES were at reduced risk for an event compared to patients with skeletal tumors (HR = 0.69; 95% CI: 0.50–0.95; $P = 0.02$).

Next, we evaluated whether the type of relapse differed between patients with EES and skeletal ES. There were no statistically significant differences in the cumulative incidence of local, distant, or combined relapses between the two groups, though there was a trend to suggest higher incidence of isolated distant failure in patients with skeletal ES (data not shown).

TABLE 1 Comparison of clinical features between patients with extraskletal versus skeletal localized Ewing sarcoma

Characteristic	Extraskletal ^d (n = 213)	Skeletal ^d (n = 826)	P-value
Median age (range), years	12 (0–30)	12 (0–45)	0.46 ^a
Age			0.91 ^b
<18 years	187 (88%)	721 (87%)	
≥18 years	26 (12%)	105 (13%)	
Sex			1.0 ^b
Male	116 (55%)	449 (54%)	
Female	97 (45%)	377 (46%)	
Race			<0.001 ^b
White	172 (81%)	721 (87%)	
Nonwhite	29 (14%)	51 (6%)	
Unknown	12 (6%)	54 (7%)	
Primary site			<0.001 ^c
Distal extremity	22 (10%)	191 (23%)	
Proximal extremity	34 (16%)	179 (22%)	
Pelvis	29 (14%)	160 (19%)	
Spinal/paraspinal	15 (7%)	76 (9%)	
Thorax/abdomen	92 (43%) ^e	164 (20%)	
Head and neck	17 (8%)	56 (7%)	
Unknown	4 (2%)	0 (0%)	
Primary site			<0.001 ^b
Axial	153 (72%)	456 (55%)	
Nonaxial	56 (26%)	370 (45%)	
Unknown	4 (2%)	0 (0%)	
Primary site			0.07 ^b
Pelvic	29 (14%)	160 (19%)	
Nonpelvic	180 (85%)	666 (81%)	
Unknown	4 (2%)	0 (0%)	
Median tumor size (interquartile range), cm	6 (4–9)	9 (6–12)	<0.001 ^a
Tumor size, cm			<0.01 ^b
≤8	44 (21%)	136 (16%)	
>8	18 (9%)	137 (17%)	
Unknown	151 (71%)	553 (67%)	
Lactate dehydrogenase (LDH)			0.44 ^b
Normal	135 (63%)	478 (58%)	
Elevated	61 (29%)	249 (30%)	
Unknown	17 (8%)	99 (12%)	
Erythrocyte sedimentation rate (ESR)			0.51 ^b
≤46 mm/hr	106 (50%)	397 (48%)	
>46 mm/hr	32 (15%)	140 (17%)	
Unknown	75 (35%)	289 (35%)	
Local control			<0.01 ^c
Surgery	99 (46%)	435 (53%)	
Radiation	34 (16%)	166 (20%)	
Surgery + radiation	63 (30%)	138 (17%)	
Unknown	17 (8%)	87 (11%)	

(Continued)

TABLE 1 (Continued)

Characteristic	Extraskeletal ^d (n = 213)	Skeletal ^d (n = 826)	P-value
Study			0.70 ^b
INT-0154	94 (44%)	377 (46%)	
AEWS0031	119 (56%)	449 (54%)	

^aTwo-sided Wilcoxon test.

^bTwo-sided Fisher exact test.

^cLikelihood ratio chi-squared test.

^dTotals do not sum to 100% due to rounding.

^eIncludes 13 cases of primary renal Ewing sarcoma.

Next, we focused exclusively on patients with EES. We first performed a univariate analysis of EFS and found that age, race, and ESR were significantly associated with risk of an event (Table 2). These variables were also significant predictors of OS, though we also observed a trend in which patients with pelvic EES had superior OS (HR = 0.18; 95% CI: 0.02–1.29; $P = 0.09$; Table 2). We then constructed a Cox proportional hazards model to identify independent prognostic factors for EFS just in the EES group. Age ≥ 18 (HR 2.87; 95% CI: 1.28–6.45; $P = 0.01$), nonwhite race (HR 2.86; 95% CI: 1.31–6.25; $P < 0.01$), and elevated baseline ESR (HR 2.68; 95% CI: 1.29–5.54; $P < 0.01$) were independently associated with inferior outcome. Due to the extensive amount of missing data regarding tumor size in patients with EES, we were not able to include this variable in our multivariate model.

3.3 | Biologic Features in EES and Skeletal ES

Data on *EWSR1* translocation status, *TP53* mutation, and *CDKN2A* status were available for 112, 93, and 107 patients, respectively, whose tumors have previously been profiled and results published (Table 3).^{10,11} There were no differences in the frequency of harboring any *EWSR1* translocation ($P = 0.84$) or, among those with *EWSR1/FLI1* translocations, in the subtype of *EWSR1/FLI1* translocation ($P = 0.33$) between EES and skeletal ES. Likewise, the frequency of *TP53* mutation or *CDKN2A* mutation/loss did not differ between EES and skeletal ES.

We next compared gene expression profiles between EES and skeletal ES in 46 tumors previously profiled as part of an earlier study.¹² As previously reported, unsupervised hierarchical clustering of these 46 tumors with available data failed to discriminate EES and skeletal ES. Similarly, supervised hierarchical clustering of these tumors did not yield a clear differential pattern of gene expression between these two clinical groups at a whole genome level (Fig. 2A). To determine if significant differences in expression exist at the level of individual genes or gene families, we performed transcript-level analyses, as described in Section 2. These analyses identified 119 genes as being differentially expressed between EES and skeletal tumors. Forty-six genes were more highly expressed in EES tumors while 73 were relatively upregulated in bone tumors (Fig. 2B). Gene ontology analysis revealed a significant enrichment of skeletal system development and extracellular matrix genes among the 73 bone tumor-associated genes (Fig. 2C). No specific biologic processes were enriched among EES tumor-associated genes.

4 | DISCUSSION

In this large cohort of patients with localized ES treated with modern chemotherapy protocols, we confirmed that there are important clinical differences between patients with EES and skeletal ES. We




FIGURE 1 Kaplan-Meier estimates comparing 5-year (A) event-free survival (EFS) and (B) overall survival (OS) between patients with extraskeletal versus skeletal localized Ewing sarcoma

TABLE 2 Results of univariate analysis of event-free and overall survival for patients with localized extraskeletal Ewing sarcoma

Characteristic	HR for event (95% CI)	P-value ^a	HR for death (95% CI)	P-value ^a
Age		0.005		0.003
<18 years	Ref		Ref	
≥18 years	2.63 (1.35–5.12)		3.14 (1.47–6.69)	
Sex		0.74		0.84
Female	Ref		Ref	
Male	0.91 (0.53–1.56)		1.07 (0.56–2.04)	
Race		0.003		0.001
White	Ref		Ref	
Nonwhite	2.62 (1.39–4.95)		3.51 (1.71–7.22)	
Primary site		0.53		0.17
Thorax/abdomen	Ref		Ref	
Distal extremity	0.48 (0.14–1.60)		0.69 (0.20–2.35)	
Proximal extremity	1.25 (0.61–2.55)		1.36 (0.60–3.05)	
Pelvis	0.63 (0.24–1.66)		0.18 (0.02–1.36)	
Spinal/paraspinal	1.31 (0.50–3.44)		1.44 (0.48–4.28)	
Head and neck	0.81 (0.28–2.33)		0.57 (0.13–2.46)	
Primary site		0.99		0.44
Nonaxial	Ref		Ref	
Axial	1.01 (0.54–1.86)		0.76 (0.38–1.52)	
Primary Site		0.35		0.09
Nonpelvic	Ref		Ref	
Pelvic	0.64 (0.26–1.62)		0.18 (0.02–1.29)	
Tumor size, cm		0.73		0.81
≤6	Ref		Ref	
>6	0.85 (0.34–2.12)		1.14 (0.40–3.25)	
Lactate dehydrogenase (LDH)		0.93		0.26
Normal	Ref		Ref	
Elevated	1.03 (0.56–1.88)		1.49 (0.75–2.95)	
Erythrocyte sedimentation rate (ESR)		0.01		0.01
≤46 mm/hr	Ref		Ref	
>46 mm/hr	2.49 (1.25–4.96)		3.02 (1.33–6.83)	
Study		0.06		0.14
AEWS0031	Ref		Ref	
INT-0154	1.69 (0.97–2.94)		1.68 (0.85–3.32)	

HR, hazard ratio; Ref, reference group; CI, confidence interval.

^aP-value, relative hazard, and 95% confidence interval calculated using a proportional hazards regression model with the noted characteristic as the only variable in the model.

also found that extraskeletal tumor origin is a favorable prognostic factor, independent of age, race, and tumor site. We determined that older age, nonwhite race, and elevated baseline ESR are independent adverse prognostic factors in patients with EES. We found that the pattern of relapse does not differ between patients with EES and skeletal ES. We did not find significant differences in key genomic features between extraskeletal or skeletal tumors, a null finding that nevertheless improves our understanding of potential biological differences between groups. We also highlight differences in gene expression between these two groups.

Consistent with previous reports, we found that EES accounts for 20.5% of cases of ES.¹ We confirmed the findings of previous studies, which showed that compared to patients with skeletal ES, patients with EES are more likely to be nonwhite with a nonpelvic, axial primary site. Data comparing tumor size between EES and skeletal ES are conflicting. Some studies have shown that EES tumors are smaller at diagnosis, while others have shown no difference.^{1,3,7,16} We observed that patients with EES were more likely to have smaller tumors (<8 cm) compared to patients with skeletal ES. Interestingly, patients with EES having a pelvic primary site showed a trend toward improved OS,

TABLE 3 Comparison of biologic features between patients with extraskelatal versus skeletal localized Ewing sarcoma

Characteristic	Extraskelatal	Skeletal	P-value ^a
Translocation			0.84
EWSR1-FLI1	22 (78%)	67 (81%)	
Other	3 (11%)	6 (7%)	
Negative	3 (11%)	10 (12%)	
EWSR1-FLI1 Translocation			0.33
Type 1	15 (68%)	44 (66%)	
Type 2	6 (27%)	12 (18%)	
Other	1 (5%)	11 (16%)	
TP53 mutation			0.18
Mutation	3 (17%)	5 (7%)	
Normal	15 (83%)	70 (93%)	
CDKN2A mutation/loss			1.0
Yes	2 (9%)	10 (12%)	
No	21 (91%)	74 (88%)	

^aTwo-sided Fisher exact test.

suggesting that this known adverse prognostic factor in skeletal ES may have the opposite effect in EES. Patients with EES in our study were more likely to receive a combined modality approach (surgery plus radiation) for local control. This is potentially due to the higher proportion of axial tumors seen in EES, a site that may be less amenable to complete resection with negative margins. Alternatively, it is

possible that these patients were more likely to undergo upfront excisional biopsy without adequate margins, necessitating subsequent radiotherapy. Our results support a higher rate of positive surgical margins in this group of patients.

Prior studies have suggested that the outcomes for EES and skeletal ES are similar when treated with ES protocols.^{3-6,17,18} However, two more recently published studies reported improved survival for EES in comparison to skeletal ES.^{1,7} Our findings are consistent with these more recent observations and increase the evidence base supporting a more favorable outcome for EES. The etiology for this pattern is not clear. While patients with EES were more likely to receive combined modality local control, previous analyses have not demonstrated improved outcomes with this approach, making this an unlikely explanation for the observed differences.^{16,19} Differences in key genomic features in this disease are not a likely explanation, as we did not observe such differences in our analysis. However, differential distribution of chemotherapy to bone versus soft-tissue sites and other differences in tumor microenvironment and angiogenesis identified in our gene expression analysis may provide clues for future investigation.

Prognostic factors identified specifically in patients with EES were similar to patients reported for ES in general.²⁰⁻²² Elevated baseline ESR was significantly associated with inferior EFS among patients with EES. Elevated ESR has been reported as an adverse prognostic factor in a variety of adult and pediatric cancers, including ES in some studies.²³⁻³¹ For the first time, we report the significance of ESR in patients with localized EES. ESR is known to be a marker of systemic inflammation, but the exact explanation for its prognostic implications




FIGURE 2 (A) Supervised hierarchical clustering reveals that genome wide expression profiles of extraskelatal and skeletal Ewing sarcoma tumors are largely equivalent. Clustering performed using 4,615 annotated and expressed genes. (B) Supervised clustering of differentially expressed genes (N = 119 genes) between skeletal and extraskelatal Ewing sarcoma tumors (N = 46 tumors). Clustering limited to genes with fold changes of >1.5 and $P < 0.05$. (C) Top 10 most enriched biologic processes among genes that are upregulated in skeletal compared to extraskelatal tumors

in cancer remains unclear. There is a growing body of evidence that shows the importance of inflammation in all stages of tumor development, from initiation, to malignant transformation, to local invasion, and establishment of metastatic niche.^{32–35} Additionally, inflammatory cells have been shown to contribute to angiogenesis, immune suppression, and the establishment of the tumor microenvironment, which has been proven to be indispensable to the malignant conversion of cells and to the survival of the tumor.^{32–35} Alternatively, increased ESR could be a marker of greater systemic burden of disease not appreciable on imaging (i.e., micrometastases), though we did not find that baseline LDH was prognostic in EES.

Recent literature has described a rare subset of highly aggressive *EWSR1* translocation-negative sarcomas that have distinct genetic signatures and have been referred to as undifferentiated small round cell sarcomas or Ewing-like sarcomas.^{36–41} Of the patients with available translocation status available, our study included 13 translocation-negative tumors. While it is possible that our cohort included tumors harboring one of the mutations commonly seen in Ewing-like sarcomas such as *CIC-DUX4* or *BCOR-CCNB3*, the potential impact on our study is minimal given the small proportion of translocation-negative tumors and the fact that these tumors were balanced between groups.

One of the main strengths of our study was our ability to analyze a large cohort of patients with EES treated with modern chemotherapy protocols and compare them to patients with skeletal ES. Being able to confirm the diagnosis of EES for patients with EES by review of the institutional baseline imaging reports increased the reliability of this designation in our study. We provide a description of the biologic features and genetic profiling in the largest cohort of patients with EES. However, the conclusions that can be drawn from these comparisons are limited due to the relatively small sample size with available biological parameters. An additional limitation was that we lacked tumor size data on over half of the entire cohort, which limited our ability to control for this well-established prognostic factor in our multivariate models. Since patients with EES tended to have smaller tumors, differences in tumor size could potentially confound our observed relationship between tissue origin and prognosis. It is also possible that specific rare subgroups such as cutaneous ES may behave differently than the entire subgroup of EES.⁴² We also acknowledge that the group of patients enrolled to COG studies is enriched for younger patients. This may account for the fact that we did not note a difference in age distribution between EES and skeletal ES, as has been reported by others.¹ In order to evaluate a more homogeneous patient population treated with similar chemotherapy, we focused our analysis on patients with localized disease. The extent to which our findings will generalize to patients with metastatic disease is unknown. We were also unable to confirm extraskeletal origin for all patients, particularly for patients on trial INT-0154. However, a sensitivity analysis focused exclusively on patients from AEWS0031 confirmed that patients with EES have superior EFS compared to patients with skeletal ES. Finally, while all patients received five-drug therapy typical for this disease in North America, our sample size precluded subanalyses based on randomized arm of each of the included trials.

In conclusion, we demonstrate that clinical characteristics, but not key tumor genomic features, differ between patients with EES and

skeletal ES. For the first time, we report differences in gene expression between these two groups. Prognostic factors in EES are similar to those established in patients with skeletal disease and ESR provides additional prognostic information. Additional efforts should be made to obtain specimens for biologic testing and gene profiling so that more robust comparisons of the genomic features analyzed in our study as well as newer mutations such as *STAG2* can be made between these two groups of patients. While outcomes are statistically superior for EES, the clinical difference is relatively modest. This finding together with the rarity of ES supports the current practice of treating these two subgroups with similar approaches.

ACKNOWLEDGEMENTS

We acknowledge the assistance of Lei Huang with gene expression profile analyses, as well as Caihong Xia and Yun Gao with statistical analysis. This study was supported by the Nick Currey Fund and NIH/NCI U10 CA98543. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

CONFLICT OF INTEREST

None of the authors have any conflicts of interest related to this work or its publication. Author S.L.L. has a leadership role and stock/ownership interest in Salarius Pharmaceuticals.

ABBREVIATIONS

CI	confidence interval
COG	Children's Oncology Group
ES	Ewing sarcoma
EES	extraskeletal Ewing sarcoma
EFS	event-free survival
ESR	erythrocyte sedimentation rate
HR	hazard ratio
IRB	Institutional Review Board
LDH	lactate dehydrogenase
OS	overall survival
PNET	primitive neuroectodermal tumor

REFERENCES

- Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. *Cancer*. 2011;117:3027–3032.
- Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for non-metastatic Ewing sarcoma family of tumors: A Children's Oncology Group Study. *J Clin Oncol*. 2009;27:2536–2541.
- Castex MP, Rubie H, Stevens MC, et al. Extrasosseous localized ewing tumors: Improved outcome with anthracyclines—The French society of pediatric oncology and international society of pediatric oncology. *J Clin Oncol*. 2007;25:1176–1182.
- Raney RB, Asmar L, Newton WA Jr, et al. Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. *J Clin Oncol*. 1997;15:574–582.
- Gururangan S, Marina NM, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extrasosseous

- Ewing's tumor with Ewing's-directed therapy. *J Pediatr Hematol Oncol.* 1998;20:55–61.
6. Lee JA, Kim DH, Lim JS, et al. Soft-tissue Ewing sarcoma in a low-incidence population: Comparison to skeletal Ewing sarcoma for clinical characteristics and treatment outcome. *Jpn J Clin Oncol.* 2010;40:1060–1067.
 7. Biswas B, Shukla NK, Deo SV, et al. Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma. *Pediatr Blood Cancer.* 2014;61:1925–1931.
 8. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. *J Clin Oncol.* 2012;30:4148–4154.
 9. Karski EE, McIlvaine E, Segal MR, et al. Identification of discrete prognostic groups in Ewing sarcoma. *Pediatr Blood Cancer.* 2016;63:47–53.
 10. van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: A report from the Children's Oncology Group. *J Clin Oncol.* 2010;28:1989–1994.
 11. Lerman DM, Monument MJ, McIlvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. *Pediatr Blood Cancer.* 2015;62:759–765.
 12. Volchenboum SL, Andrade J, Huang L, et al. Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: A report from the Children's Oncology Group. *J Path Clin Res.* 2015;1:83–94.
 13. Marubini E, Valsecchi MG. *Analysing Survival Data from Clinical Trials and Observational Studies.* New York: John Wiley and Sons; 1995.
 14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc.* 1999;94:496–509.
 15. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc.* 2009;4:44–57.
 16. Orr WS, Denbo JW, Billups CA, et al. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital experience. *Ann Surg Oncol.* 2012;19:3816–3822.
 17. El Weshi A, Allam A, Ajarim D, et al. Extraskelatal Ewing's sarcoma family of tumours in adults: Analysis of 57 patients from a single institution. *Clin Oncol.* 2010;22:374–381.
 18. van den Berg H, Heinen RC, van der Pal HJ, Merks JH. Extra-osseous Ewing sarcoma. *Pediatr Hematol Oncol.* 2009;26:175–185.
 19. DuBois SG, Krailo MD, Gebhardt MC, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. *Cancer.* 2015;121:467–475.
 20. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's sarcoma Study Group. *J Clin Oncol.* 2000;18:3108–3114.
 21. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. *J Clin Oncol.* 2000;18:4–11.
 22. Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. *Cancer.* 2010;116:1964–1973.
 23. Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. *Anticancer Res.* 2014;34:339–347.
 24. Sengupta S, Lohse CM, Chevillat JC, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. *Cancer.* 2006;106:304–312.
 25. Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. *Clin Lab Haematol.* 2003;25:41–46.
 26. Johansson JE, Sigurdsson T, Holmberg L, Bergström R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population-based consecutive cases. *Cancer.* 1992;7:1556–1563.
 27. Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease: The EORTC Lymphoma Cooperative Group. *Ann Intern Med.* 1991;114:361–365.
 28. Ilić I, Manojlović S, Cepulić M, Orlić D, Seiwerth S. Osteosarcoma and Ewing's sarcoma in children and adolescents: Retrospective clinicopathological study. *Croat Med J.* 2004;45:740–745.
 29. Oberlin O, Deley MC, Bui BN, et al. French Society of Paediatric Oncology. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: The third study of the French Society of Paediatric Oncology (EW88 study). *Br J Cancer.* 2001;85:1646–1654.
 30. Aparicio J, Munárriz B, Pastor M, et al. Long-term follow-up and prognostic factors in Ewing's sarcoma: A multivariate analysis of 116 patients from a single institution. *Oncology.* 1998;55:20–26.
 31. Bacci G, Ferrari S, Rosito P, et al. Ewing's sarcoma of the bone. Anatomico-clinical study of 424 cases. *Minerva Pediatr.* 1992;44:345–359.
 32. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell.* 2010;140:883–899.
 33. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002;420:860–867.
 34. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res.* 2006;4:221–233.
 35. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. *Cell.* 2011;144:646–674.
 36. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. *World Health Organization Classification of Tumours of Soft Tissue and Bone.* 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2013.
 37. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. *Genes Chromosomes Cancer.* 2012;51:207–218.
 38. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. *Nat Genet.* 2012;44:461–466.
 39. Sugita S, Arai Y, Tonooka A, et al. A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: A genetically distinct variant of Ewing-like sarcoma. *Am J Surg Pathol.* 2014;38:1571–1576.
 40. Antonescu C. Round cell sarcomas beyond Ewing: Emerging entities. *Histopathology* 2014;64:26–37.
 41. Specht K, Sung YS, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged ewing sarcomas: Further evidence toward distinct pathologic entities. *Genes Chromosomes Cancer.* 2014;53:622–663.
 42. Delaplace M, Lhomme C, de Pinieux G, Vergier B, de Muret A, Machel L. Primary cutaneous Ewing sarcoma: A systematic review focused on treatment and outcome. *Br J Dermatol.* 2012;166:721–726.